{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"7.3","value":"5.7"},{"groupId":"OG001","lowerLimit":"4.7","upperLimit":"14.6","value":"7.2"},{"groupId":"OG002","lowerLimit":"1.7","upperLimit":"6.5","value":"3.7"},{"groupId":"OG003","lowerLimit":"3.7","upperLimit":"11.6","value":"5.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"description":"PFS is defined as the interval between first dose and the earliest date of disease progression or death due to any cause. No hypothesis testing completed for cohort A,B,C and D","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.","id":"OG000","title":"Cohort A"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG001","title":"Cohort B"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG002","title":"Cohort C"},{"description":"Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity","id":"OG003","title":"Cohort D"}],"paramType":"MEDIAN","populationDescription":"All Treated population - All subjects who receive at least one dose of study medication are comprised the All Treated subjects (ATS) population","reportingStatus":"POSTED","timeFrame":"From the first dose to the earliest date of disease progression or death","title":"Progression-free Survival (PFS) for Each Cohort Based on Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Month"}